Trials
Search / Trial NCT06446661

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Young Adults With Acute Lymphoblastic Leukemia

Launched by UNIVERSITY OF CHICAGO · May 31, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Not yet recruiting

Keywords

Oral Chemotherapy

ClinConnect Summary

This study aims to compare adherence to oral mercaptopurine and methotrexate during the first 84-day cycle of maintenance therapy for adolescent and young adult patients with Acute Lymphoblastic Leukemia on pediatric-based regimens between those who receive the high intensity text message intervention and those who receive standard-of-care. It is believed that high-intensity text messages will increase patient adherence within cycle 1.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Age of 15-39 years-old at the time of initial ALL diagnosis
  • • Diagnosed with ALL
  • • Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance.
  • Exclusion Criteria:
  • • Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
  • • Patient does not wish to participate

Trial Officials

Wendy Stock

Principal Investigator

University of Chicago

About University Of Chicago

The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.

Locations

Chicago, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0